Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Reply to Darcis and Berkhout.

Wijting IEA, Lungu C, Rijnders BJA, van der Ende ME, Pham HT, Mesplede T, Pas SD, Voermans JJC, Schuurman R, van de Vijver DAMC, Boers PHM, Gruters RA, Boucher CAB, van Kampen JJA.

J Infect Dis. 2018 Nov 5;218(12):2020-2021. doi: 10.1093/infdis/jiy475. No abstract available.

PMID:
30085047
2.

HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy.

Wijting IEA, Lungu C, Rijnders BJA, van der Ende ME, Pham HT, Mesplede T, Pas SD, Voermans JJC, Schuurman R, van de Vijver DAMC, Boers PHM, Gruters RA, Boucher CAB, van Kampen JJA.

J Infect Dis. 2018 Jul 24;218(5):688-697. doi: 10.1093/infdis/jiy176.

PMID:
29617822
3.

Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment.

van den Ham HJ, Cooper JD, Tomasik J, Bahn S, Aerts JL, Osterhaus ADME, Gruters RA, Andeweg AC; DC-TRN trial investigators.

PLoS One. 2018 Feb 1;13(2):e0192278. doi: 10.1371/journal.pone.0192278. eCollection 2018.

4.

DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift.

de Goede AL, Andeweg AC, van den Ham HJ, Bijl MA, Zaaraoui-Boutahar F, van IJcken WF, Wilgenhof S, Aerts JL, Gruters RA, Osterhaus AD; DC-TRN trial investigators.

Vaccine. 2015 Jun 9;33(25):2922-9. doi: 10.1016/j.vaccine.2015.04.047. Epub 2015 Apr 24.

PMID:
25913415
5.

von Willebrand Factor is elevated in HIV patients with a history of thrombosis.

van den Dries LW, Gruters RA, Hövels-van der Borden SB, Kruip MJ, de Maat MP, van Gorp EC, van der Ende ME.

Front Microbiol. 2015 Mar 11;6:180. doi: 10.3389/fmicb.2015.00180. eCollection 2015.

6.

Understanding HIV infection for the design of a therapeutic vaccine. Part II: Vaccination strategies for HIV.

de Goede AL, Vulto AG, Osterhaus AD, Gruters RA.

Ann Pharm Fr. 2015 May;73(3):169-79. doi: 10.1016/j.pharma.2014.11.003. Epub 2014 Dec 17. Review.

PMID:
25528627
7.

Understanding HIV infection for the design of a therapeutic vaccine. Part I: Epidemiology and pathogenesis of HIV infection.

de Goede AL, Vulto AG, Osterhaus AD, Gruters RA.

Ann Pharm Fr. 2015 Mar;73(2):87-99. doi: 10.1016/j.pharma.2014.11.002. Epub 2014 Dec 12. Review.

PMID:
25496723
8.

HIV-1 evolution in patients undergoing immunotherapy with Tat, Rev, and Nef expressing dendritic cells followed by treatment interruption.

de Goede AL, van Deutekom HW, Vrancken B, Schutten M, Allard SD, van Baalen CA, Osterhaus AD, Thielemans K, Aerts JL, Keşmir C, Lemey P, Gruters RA.

AIDS. 2013 Nov 13;27(17):2679-89. doi: 10.1097/01.aids.0000433813.67662.92.

PMID:
24149085
9.

The efficiency of Vpx-mediated SAMHD1 antagonism does not correlate with the potency of viral control in HIV-2-infected individuals.

Yu H, Usmani SM, Borch A, Krämer J, Stürzel CM, Khalid M, Li X, Krnavek D, van der Ende ME, Osterhaus AD, Gruters RA, Kirchhoff F.

Retrovirology. 2013 Mar 5;10:27. doi: 10.1186/1742-4690-10-27.

10.

Dried matrix on paper disks: the next generation DBS microsampling technique for managing the hematocrit effect in DBS analysis.

Meesters RJ, Zhang J, van Huizen NA, Hooff GP, Gruters RA, Luider TM.

Bioanalysis. 2012 Aug;4(16):2027-35. doi: 10.4155/bio.12.175.

PMID:
22946918
11.

Induction of humoral and cellular immune responses by antigen-expressing immunostimulatory liposomes.

Amidi M, van Helden MJ, Tabataei NR, de Goede AL, Schouten M, de Bot V, Lanzi A, Gruters RA, Rimmelzwaan GF, Sijts AJ, Mastrobattista E.

J Control Release. 2012 Dec 28;164(3):323-30. doi: 10.1016/j.jconrel.2012.08.016. Epub 2012 Aug 21.

PMID:
22940204
12.

Efficient Nef-mediated downmodulation of TCR-CD3 and CD28 is associated with high CD4+ T cell counts in viremic HIV-2 infection.

Khalid M, Yu H, Sauter D, Usmani SM, Schmokel J, Feldman J, Gruters RA, van der Ende ME, Geyer M, Rowland-Jones S, Osterhaus AD, Kirchhoff F.

J Virol. 2012 May;86(9):4906-20. doi: 10.1128/JVI.06856-11. Epub 2012 Feb 15.

13.

Sequence evolution and escape from specific immune pressure of an HIV-1 Rev epitope with extensive sequence similarity to human nucleolar protein 6.

Allard SD, de Goede AL, De Keersmaecker B, Heirman C, Lacor P, Osterhaus AD, Demanet C, Thielemans K, Gruters RA, Aerts JL.

Tissue Antigens. 2012 Mar;79(3):174-85. doi: 10.1111/j.1399-0039.2012.01837.x.

PMID:
22309258
14.

Current and future applications of dried blood spots in viral disease management.

Snijdewind IJ, van Kampen JJ, Fraaij PL, van der Ende ME, Osterhaus AD, Gruters RA.

Antiviral Res. 2012 Mar;93(3):309-21. doi: 10.1016/j.antiviral.2011.12.011. Epub 2012 Jan 5. Review.

PMID:
22244848
15.

A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption.

Allard SD, De Keersmaecker B, de Goede AL, Verschuren EJ, Koetsveld J, Reedijk ML, Wylock C, De Bel AV, Vandeloo J, Pistoor F, Heirman C, Beyer WE, Eilers PH, Corthals J, Padmos I, Thielemans K, Osterhaus AD, Lacor P, van der Ende ME, Aerts JL, van Baalen CA, Gruters RA.

Clin Immunol. 2012 Mar;142(3):252-68. doi: 10.1016/j.clim.2011.10.010. Epub 2011 Nov 16.

PMID:
22177848
16.

Comprehensive analysis of the intracellular metabolism of antiretroviral nucleosides and nucleotides using liquid chromatography-tandem mass spectrometry and method improvement by using ultra performance liquid chromatography.

Coulier L, Gerritsen H, van Kampen JJ, Reedijk ML, Luider TM, Osterhaus AD, Gruters RA, Brüll L.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Sep 15;879(26):2772-82. doi: 10.1016/j.jchromb.2011.07.045. Epub 2011 Aug 6.

PMID:
21862423
17.

Dried blood spot UHPLC-MS/MS analysis of oseltamivir and oseltamivircarboxylate--a validated assay for the clinic.

Hooff GP, Meesters RJ, van Kampen JJ, van Huizen NA, Koch B, Al Hadithy AF, van Gelder T, Osterhaus AD, Gruters RA, Luider TM.

Anal Bioanal Chem. 2011 Jul;400(10):3473-9. doi: 10.1007/s00216-011-5050-z. Epub 2011 May 3.

18.

Determination of the antiretroviral drug tenofovir in plasma from HIV-infected adults by ultrafast isotope dilution MALDI-triple quadrupole tandem mass spectrometry.

Meesters RJ, van Kampen JJ, Scheuer RD, van der Ende ME, Gruters RA, Luider TM.

J Mass Spectrom. 2011 Mar;46(3):282-9. doi: 10.1002/jms.1897.

PMID:
21394844
19.

Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots.

Meesters RJ, van Kampen JJ, Reedijk ML, Scheuer RD, Dekker LJ, Burger DM, Hartwig NG, Osterhaus AD, Luider TM, Gruters RA.

Anal Bioanal Chem. 2010 Sep;398(1):319-28. doi: 10.1007/s00216-010-3952-9. Epub 2010 Jul 15.

20.

Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometry.

van Kampen JJ, Reedijk ML, Burgers PC, Dekker LJ, Hartwig NG, van der Ende IE, de Groot R, Osterhaus AD, Burger DM, Luider TM, Gruters RA.

PLoS One. 2010 Jul 1;5(7):e11409. doi: 10.1371/journal.pone.0011409. Erratum in: PLoS One. 2010;5(7). doi: 10.1371/annotation/9e6e8b98-cc08-47be-9ab1-3f1928e12fed.

21.

Biomedical application of MALDI mass spectrometry for small-molecule analysis.

van Kampen JJ, Burgers PC, de Groot R, Gruters RA, Luider TM.

Mass Spectrom Rev. 2011 Jan-Feb;30(1):101-20. doi: 10.1002/mas.20268. Review.

PMID:
20169623
22.

Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag.

de Goede AL, Boers PH, Dekker LJ, Osterhaus AD, Gruters RA, Rimmelzwaan GF.

Vaccine. 2009 Sep 25;27(42):5735-9. doi: 10.1016/j.vaccine.2009.07.032. Epub 2009 Jul 31.

PMID:
19647812
23.

A mass spectrometry based imaging method developed for the intracellular detection of HIV protease inhibitors.

Dekker LJ, van Kampen JJ, Reedijk ML, Burgers PC, Gruters RA, Osterhaus AD, Luider TM.

Rapid Commun Mass Spectrom. 2009 Apr;23(8):1183-8. doi: 10.1002/rcm.3981.

PMID:
19283784
24.

Vaccine-induced enhancement of viral infections.

Huisman W, Martina BE, Rimmelzwaan GF, Gruters RA, Osterhaus AD.

Vaccine. 2009 Jan 22;27(4):505-12. doi: 10.1016/j.vaccine.2008.10.087. Epub 2008 Nov 18. Review.

PMID:
19022319
25.

FATT-CTL assay for detection of antigen-specific cell-mediated cytotoxicity.

van Baalen CA, Gruters RA, Berkhoff EG, Osterhaus AD, Rimmelzwaan GF.

Cytometry A. 2008 Nov;73(11):1058-65. doi: 10.1002/cyto.a.20613.

26.

Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef.

Allard SD, Pletinckx K, Breckpot K, Heirman C, Bonehill A, Michiels A, van Baalen CA, Gruters RA, Osterhaus AD, Lacor P, Thielemans K, Aerts JL.

Vaccine. 2008 Jul 4;26(29-30):3735-41. doi: 10.1016/j.vaccine.2008.04.077. Epub 2008 May 20.

PMID:
18539368
27.

Quantitative analysis of antiretroviral drugs in lysates of peripheral blood mononuclear cells using MALDI-triple quadrupole mass spectrometry.

van Kampen JJ, Burgers PC, Gruters RA, Osterhaus AD, de Groot R, Luider TM, Volmer DA.

Anal Chem. 2008 Jul 1;80(13):4969-75. doi: 10.1021/ac800218a. Epub 2008 Jun 6.

PMID:
18533679
28.

Quantitative analysis of HIV-1 protease inhibitors in cell lysates using MALDI-FTICR mass spectrometry.

van Kampen JJ, Burgers PC, de Groot R, Osterhaus AD, Reedijk ML, Verschuren EJ, Gruters RA, Luider TM.

Anal Chem. 2008 May 15;80(10):3751-6. doi: 10.1021/ac702072c. Epub 2008 Apr 8.

PMID:
18393531
29.

The loss of immunodominant epitopes affects interferon-gamma production and lytic activity of the human influenza virus-specific cytotoxic T lymphocyte response in vitro.

Berkhoff EG, Geelhoed-Mieras MM, Verschuren EJ, van Baalen CA, Gruters RA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

Clin Exp Immunol. 2007 May;148(2):296-306. Epub 2007 Feb 26.

30.

Validation of an HIV-1 inactivation protocol that is compatible with intracellular drug analysis by mass spectrometry.

van Kampen JJ, Verschuren EJ, Burgers PC, Luider TM, de Groot R, Osterhaus AD, Gruters RA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Feb 15;847(1):38-44. Epub 2006 Oct 20.

PMID:
17055786
31.

Fluorescent antigen-transfected target cell cytotoxic T lymphocyte assay for ex vivo detection of antigen-specific cell-mediated cytotoxicity.

van Baalen CA, Kwa D, Verschuren EJ, Reedijk ML, Boon AC, de Mutsert G, Rimmelzwaan GF, Osterhaus AD, Gruters RA.

J Infect Dis. 2005 Oct 1;192(7):1183-90. Epub 2005 Aug 30.

PMID:
16136460
32.

HIV and Smallpox.

Gruters RA, Osterhaus AD.

Science. 2005 May 27;308(5726):1258-9; author reply 1258-9. No abstract available.

PMID:
15919975
33.

CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia.

Blaak H, Boers PH, Gruters RA, Schuitemaker H, van der Ende ME, Osterhaus AD.

J Virol. 2005 Feb;79(3):1686-700.

34.

SIVdrl detection in captive mandrills: are mandrills infected with a third strain of simian immunodeficiency virus?

van der Kuyl AC, van den Burg R, Hoyer MJ, Gruters RA, Osterhaus AD, Berkhout B.

Retrovirology. 2004 Nov 1;1:36.

35.

The choice of antigen for therapeutic immunization against AIDS.

van Baalen CA, Stittelaar KJ, Osterhaus AD, Guillon C, Gruters RA.

Trends Immunol. 2002 Oct;23(10):478-9.

PMID:
12297418
36.

Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes.

van Baalen CA, Guillon C, van Baalen M, Verschuren EJ, Boers PH, Osterhaus AD, Gruters RA.

Eur J Immunol. 2002 Sep;32(9):2644-52.

37.

Seeing stars.

Gruters RA.

Nature. 2002 Aug 29;418(6901):915. No abstract available.

PMID:
12198519
38.

Comparison of the efficacy of early versus late viral proteins in vaccination against SIV.

Stittelaar KJ, Gruters RA, Schutten M, van Baalen CA, van Amerongen G, Cranage M, Liljeström P, Sutter G, Osterhaus AD.

Vaccine. 2002 Jul 26;20(23-24):2921-7.

PMID:
12126903
39.

The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes.

Gruters RA, van Baalen CA, Osterhaus AD.

Vaccine. 2002 May 6;20(15):2011-5. Review.

PMID:
11983265
41.

Construction and characterisation of infectious recombinant HIV-1 clones containing CTL epitopes from structural proteins in Nef.

Guillon C, van Baalen CA, Boers PH, Verschuren EJ, Gruters RA, Osterhaus AD.

J Virol Methods. 2002 Jan;99(1-2):115-21.

PMID:
11684309
42.

Macrophage tropism of human immunodeficiency virus type 1 facilitates in vivo escape from cytotoxic T-lymphocyte pressure.

Schutten M, van Baalen CA, Guillon C, Huisman RC, Boers PH, Sintnicolaas K, Gruters RA, Osterhaus AD.

J Virol. 2001 Mar;75(6):2706-9.

43.

Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy.

van der Ende ME, Guillon C, Boers PH, Ly TD, Gruters RA, Osterhaus AD, Schutten M.

J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):11-8.

PMID:
11064499
44.

Development of a real-time quantitative RT-PCR for the detection of HIV-2 RNA in plasma.

Schutten M, van den Hoogen B, van der Ende ME, Gruters RA, Osterhaus AD, Niesters HG.

J Virol Methods. 2000 Jul;88(1):81-7.

PMID:
10921845
45.

Broadening of coreceptor usage by human immunodeficiency virus type 2 does not correlate with increased pathogenicity in an in vivo model.

van Der Ende ME, Guillon C, Boers PH, Gruters RA, Racz P, Tenner-Racz K, Osterhaus AD, Schutten M.

J Gen Virol. 2000 Feb;81(Pt 2):507-13.

PMID:
10644850
46.

Vaccination with Rev and Tat against AIDS.

Osterhaus AD, van Baalen CA, Gruters RA, Schutten M, Siebelink CH, Hulskotte EG, Tijhaar EJ, Randall RE, van Amerongen G, Fleuchaus A, Erfle V, Sutter G.

Vaccine. 1999 Jun 4;17(20-21):2713-4. No abstract available.

PMID:
10418922
47.
48.
49.

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

van Baalen CA, Pontesilli O, Huisman RC, Geretti AM, Klein MR, de Wolf F, Miedema F, Gruters RA, Osterhaus AD.

J Gen Virol. 1997 Aug;78 ( Pt 8):1913-8.

PMID:
9266987
50.

Molecular characterization of HIV viruses generated after in vivo ligation.

Guillon C, Oriol G, Gruters RA.

J Virol Methods. 1997 Jul;66(2):237-46.

PMID:
9255735

Supplemental Content

Loading ...
Support Center